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Summary
Although the standard of care for cow’s milk (CM) allergy is strict food avoidance, oral immu-
notherapy (OIT) is being widely investigated as an alternative management option in certain 
cases. Immediate adverse reactions to OIT have been described, but its long-term effects are 
much less often reported.
We present the case of a girl diagnosed with IgE-mediated CM allergy that was proposed for 
our CM OIT protocol at the age of 3 years. The first sessions (dose escalation up to 5 ml) 
were well tolerated, however eight hours after her daily morning dose of 5ml CM the child 
developed late episodes of vomiting. No other symptoms, particularly immediately after CM 
ingestion, were reported. These episodes became progressively worse and on the third day she 
presented mild dehydration and blood eosinophilia. After OIT interruption, a progressive 
clinical improvement was observed. An esophageal endoscopy was performed, showing signs 
of eosinophilic esophagitis (EoE) with peak 20 eosinophils/hpf. After treatment with topical 
swallowed fluticasone (500 mcg bid) and a CM-free diet for 4 months, the child was asymp-
tomatic and endoscopy and biopsy findings were normal.
The long-term effects of milk OIT are still in part unknown. We hypothesize that eosinophilic 
esophagitis may have been a consequence of OIT in this case. The findings seem to indicate that 
food allergy may play a role in the pathogenesis of esophageal eosinophilia and stress the impor-
tance of a well programmed long-term follow-up of patients that have undergone milk OIT.
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Diagnosis of eosinophilic esophagitis in an infant 
undergoing milk oral immunotherapy - a case report
Case Report
Cow’s milk (CM) allergy is a common disorder for which the 
standard of care is strict food avoidance. In recent years, CM 
oral immunotherapy (OIT), achieved by oral exposure to in-
creasing doses of the food, has received particular attention as 
an alternative in cases where spontaneous tolerance acquisition 
is unlikely (1), increasing both quality of life and safety in the 
event of accidental ingestion of the offending food. Immedi-
ate adverse reactions during OIT have often been reported and 
seem to occur in 50 to 100% of cases (2-5). Delayed reactions, 
however, are much less often reported (3,5).
We present the case of a 3-year old girl with atopic eczema and 
CM allergy. This condition manifested at 2 months of age in 
association with several episodes of urticaria, angioedema and 
vomiting following CM ingestion. IgE-mediated allergy was 
confirmed by skin prick tests, positive serum specific IgE (sIgE) 
and a positive oral food challenge. A complete eviction of CM 
from her diet resulted in resolution of all symptoms.
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reactions associated with CM ingestion developed into late gas-
trointestinal symptoms at the third week of OIT protocol.
EoE is an immune-mediated disorder in which the esophagus 
is infiltrated by eosinophils, presumably through a TH
2
-driv-
en process (7). In this case, diagnosis was confirmed by en-
doscopy and biopsy findings. Recovery following withdrawal 
of CM suggests a probable causal relation with CM ingestion 
during OIT. As no endoscopy was performed prior to OIT, we 
can only speculate that EoE developed during the treatment. 
However, symptoms of recurrent vomiting and malaise were 
absent previously, and blood eosinophilia also developed only 
after initiation of the protocol. According to recent guidelines 
(7) proton-pump inhibitor therapy was attempted, in order to 
discard gastroesophageal reflux disease or proton-pump inhibi-
tor-responsive esophageal eosinophilia. Unfortunately, it had to 
be interrupted due to an apparent adverse reaction and a deci-
sion was made not to delay swallowed fluticasone therapy. It was 
therefore not entirely possible to exclude those diseases. Howev-
er, we consider that the fact that the child remained asymptom-
atic and free of histologic abnormalities long after interruption 
of pharmacological treatment, strongly supports the diagnosis 
of CM induced EoE.It has been hypothesized that exposure of 
the esophagus of predisposed individuals to high antigen loads 
may be the core mechanism responsible for the development 
of EoE (8). In animal models, mice with respiratory, oral or 
epicutaneous sensitization that are rechallenged with intranasal 
exposure to allergens, develop esophageal eosinophilic infiltrates 
which mimic EoE (9,10). In humans, cases of EoE have been 
attributed to large volume allergen exposures (8), aeroallergen 
sublingual immunotherapy (11) and OIT (12-14).
Our review has found reports of 4 patients who developed EoE 
following CM OIT protocols (12,13). Furthermore, OIT pro-
tocols with peanut (3) and egg (13,14) have also been implied. 
Although this condition is probably underdiagnosed, the scarci-
ty of reports suggest that EoE associated with OIT is likely rare. 
This is the first suggestive case in over 30 CM OIT performed 
in our center.
Although a favorable outcome seems to have occurred in this 
case, long-term evolution of esophageal eosinophilia and EoE is 
still uncertain. We agree with authors (12) who suggest that in 
the presence of this reaction, OIT should be interrupted.
The long-term effects of CM OIT are still in part unknown and 
adverse reactions may be more common than previously expect-
ed. The findings in this case seem to indicate that food allergy 
may play a role in the pathogenesis of esophageal eosinophilia 
and possibly of EoE and stress the importance of a well pro-
grammed long-term follow-up of patients that have undergone 
CM OIT.
At the age of 3 years and 9 months, after several immediate 
reactions with cutaneous and gastrointestinal involvement asso-
ciated with unintentional CM ingestion, and since sIgE levels 
were persistently elevated (milk: 60 KUA/L; casein: 29 KUA/L), 
the child was proposed to undergo a OIT protocol (6). Consent 
from our institution’s review board and from her parents was 
obtained prior to protocol start.
It consisted of administration of increasing doses of CM in our 
outpatient allergy center at 2 to 3 week intervals followed by 
daily consumption of the tolerated dose at home. In the first 
session, a dose of 1 ml was reached and mild immediate reac-
tions (facial urticaria, oral itching) were observed. No reactions 
occurred during the maintenance period at home, thus a new 
dose escalation was done from 1 to 5 ml after 3 weeks. Thereaf-
ter, parents were instructed to maintain a daily morning dose of 
5 ml at home. On the following day however, the child devel-
oped vomiting episodes approximately eight hours after CM in-
gestion. No other symptoms, particularly immediately after the 
dose, were reported. These episodes became progressively worse 
and on the third day she returned to the hospital. She looked 
ill and mildly dehydrated. A complete blood cell count revealed 
1020 eosinophils/mm3 (prior levels were 340 eosinophils/mm3). 
At this time point, OIT was interrupted and progressive clinical 
improvement was observed on the course of the following days.
Five days later an esophageal endoscopy was performed, show-
ing rings and white mucosal exudates with a peak of 20 eosino-
phils/hpf in mucosal biopsies from the upper, middle and lower 
esophagus. Gastric and duodenal biopsies had no alterations 
and Helicobacter pylori (HP) and Giardia lamblia were absent. 
Markers for celiac disease and HP were negative. A pH-moni-
toring test was attempted but not tolerated by the child. Sub-
sequent skin tests with other foods commonly associated with 
eosinophilic esophagitis (EoE) were negative.
Treatment was started with lanzoprazol but there was an epi-
sode of vomiting and urticaria immediately after the first dose, 
and therefore a decision was made to initiate topical swal-
lowed fluticasone therapy (500 mcg bid) immediately. After a 
4 month treatment with fluticasone and a CM-free diet, the 
child was asymptomatic and a new endoscopy with multiple 
biopsies found no alterations. Fluticasone was stopped and CM 
avoidance was maintained until now. At present, the child re-
mains symptom-free 28 months after fluticasone discontinua-
tion. Control endoscopies and biopsies performed at 12 and 27 
months showed no sign of esophagitis. Specific IgE measured 14 
months after the interruption of OIT was slightly higher (milk: 
70 KUA/L; casein: 41 KUA/L) and presently a spontaneous de-
crease is observed (milk: 34 KUA/L; casein: 27 KUA/L).
We describe a patient with a typical history of IgE-mediated 
CM allergy, who developed a different clinical profile after the 
beginning of OIT: initial immediate skin and gastrointestinal 
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